Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function
Fecha
2020-06-17
Profesor Guía
Formato del documento
Articulo
ORCID Autor
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ubicación
ISBN
ISSN
item.page.issne
item.page.doiurl
Facultad
Facultad de Ciencias
Departamento o Escuela
Instituto de Fisiologia
Determinador
Recolector
Especie
Nota general
Resumen
Maternal obesity during pregnancy and gestational diabetes mellitus (GDM) are both associated with of several postnatal diseases in the offspring, including obesity, early onset hypertension, diabetes mellitus, and reproductive alterations. Metformin is an oral drug that is being evaluated to treat GDM, obesity-associated insulin resistance, and polycystic ovary syndrome (PCOS) during pregnancy. The beneficial effects of metformin on glycemia and pregnancy outcomes place it as a good alternative for its use during pregnancy. In this line of thought, improving the metabolic status of the pregnant mother by using metformin should avoid the consequences of insulin resistance on the offspring's fetal and postnatal development. However, some human and animal studies have shown that metformin during pregnancy could amplify these alterations and be associated with excessive postnatal weight gain and obesity. In this minireview, we discuss not only the
clinical and experimental evidence that supports the benefits of using metformin during pregnancy but also the evidence showing a possible negative impact of this drug on the offspring's development.
Descripción
Lugar de Publicación
Auspiciador
Palabras clave
METFORMIN, PREGNANCY, POLYCYSTIC OVARY SYNDROME, DIABETES MELLITUS, POSTNATAL, BODYWEIGHT